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ABSTRACT
Idiopathic pulmonary fibrosis (IPF), a progressive and
fatal diffuse parenchymal lung disease, is defined
pathologically by the pattern of usual interstitial pneu-
monia (UIP). Unfortunately, a surgical lung biopsy
cannot be performed in all patients due to comorbidi-
ties that may significantly increase the morbidity and
mortality of the procedure. High-resolution computed
tomography (HRCT) has been put forth as a surrogate
to recognize pathological UIP. The quality of the HRCT
impacts the ability to make a diagnosis of UIP and
varies based on the centre performing the study and
patient factors. The evaluation of the HRCT includes
assessing the distribution and predominance of key
radiographical findings, such as honeycomb, septal
thickening, traction bronchiectasis and ground glass
attenuation lesions. The combination of the pattern
and distribution is what leads to a diagnosis and asso-
ciated confidence level. HRCT features of definite
UIP (subpleural, basal predominant honeycomb with
septal thickening, traction bronchiectasis and ground
glass attenuation lesions) have a high specificity for the
UIP pathological pattern. In such cases, surgical lung
biopsy can be avoided. There are caveats to using the
HRCT to diagnose IPF in isolation as a variety of
chronic pulmonary interstitial diseases may progress
to a UIP pattern. Referral centres with experience in
diffuse parenchymal lung disease that have multidisci-
plinary teams encompassing clinicians, radiologists
and pathologists have the highest level of agreement in
diagnosing IPF.
Key words: computed tomography, idiopathic inter-
stitial pneumonia, pulmonary fibrosis, usual interstitial
pneumonia.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive
and fatal diffuse parenchymal lung disease with
unclear pathophysiology and no clear consensus on
treatment. The incidence of IPF has been reported as
6–42 per 100 000 persons but increases with age to
more than 200 per 100 000 persons in those older than
age 75 years.1–4 The median survival for IPF is poor,
between 2–3 years. From an American Thoracic
Society/European Respiratory Society (ATS/ERS)
consensus statement on the idiopathic interstitial
pneumonias (IIP), IPF is definitively diagnosed when
lung pathology shows a usual interstitial pneumonia
(UIP) pattern in the absence of a plausible aetiology.1
Several studies have shown that in a prescribed clini-
cal setting, high-resolution computed tomography
(HRCT) of the chest with certain features can be used
as a surrogate to recognize the pathological pattern of
UIP with high degrees of confidence. This is attractive
given the possibility of acute exacerbations and high
30-day mortality following lung biopsy in patients
with resting hypoxemia, pulmonary hypertension,
immune-suppression or suffering an acute
deterioration.5–7 Because UIP can be found with many
diffuse parenchymal lung diseases, such as hypersen-
sitivity pneumonitis, collagen vascular disease, occu-
pational exposures etc., a careful multidisciplinary
approach to exclude these is essential to yielding an
accurate diagnosis of IPF.
DEFINITION OF HIGH-RESOLUTION
COMPUTED TOMOGRAPHY
The ability to make a diagnosis of UIP in part depends
on the quality of the HRCT examination. Unfortu-
nately, there are significant differences in HRCT
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technique as each institution that performs HRCT
scans defines its own technique. Therefore, the
quality and the utility of a particular HRCT scan may
be subjective. Understanding the capability of local
imaging centres may help to reduce or avoid unnec-
essary repeat HRCT scans and radiation exposure. CT
technology has changed rapidly through the years
and with that, expert opinion as to what constitutes a
satisfactory quality HRCT scan. Table 1 highlights the
current American College of Radiology recommenda-
tions for the performance of a HRCT scan.8
HRCT should be performed without i.v. iodinated
contrast material so as to prevent lung parenchymal
enhancement that may confuse ground glass attenu-
ation (GGA) lesions with normal lung tissue, espe-
cially if situated adjacent to areas of structural
abnormality, such as emphysema and atelectasis.
Reconstructing HRCT images with a high-spatial-
frequency algorithm (bone algorithm) enhances the
sharpness of lung structural abnormalities by increas-
ing the contrast between adjacent structures that
have only minor attenuation differences. Tradition-
ally, HRCT has been performed in an incremental
fashion that limited sampling to a series of 1- to 2-mm
thin sections separated every 10 or 15 mm, excluding
90% or more of the lung parenchyma. Current HRCT
using multi-detector helical scanners can provide a
volumetric dataset with narrow slice thickness images
of the entire lungs obtained during a single breath
hold. Contiguous HRCT images make it feasible to
confidently distinguish honeycomb and lung cysts
from traction bronchiectasis, as well as lung nodules
from vascular structures or mucus impaction in small
airways.
Ideally, HRCT of the lungs should include supine
end-inspiratory, supine end-expiratory and prone
end-inspiratory images. Prone HRCT images may
help to evaluate for early UIP changes at the posterior
lung bases, which may be either mimicked or
obscured by atelectasis on supine images. End-
expiratory images may reveal air trapping seen in
patients with hypersensitivity pneumonitis. To reduce
a patient’s radiation dose, expiratory and prone scan-
ning may be performed in an incremental fashion.
Patient characteristics may also affect HRCT image
quality and must be taken into account before scan-
ning. An acutely ill, tachypneic patient may have
significant respiratory motion artefact interfering
with the illustration of the lung pathology. Patients
may not be able to lie prone for scanning due to their
dyspnea. Pulmonary oedema enhances interlobular
septal thickening and generates GGA that can simu-
late alveolitis. Morbid obesity can reduce HRCT scan
signal-to-noise ratio to the extent of obscuring subtle
changes of interstitial lung disease.
Radiation dose is a concern for volumetric HRCT
scans and is variable based on patient factors, type of
CT scanner, scan parameters and HRCT protocol.
The radiation dose has a linear relationship with CT
scanner tube current. Radiation dose reduction is
achieved by adjusting tube current; however, lowering
tube current will decrease signal-to-noise ratio.9,10
Hence, it is important to obtain diagnostic quality
HRCT images using as low as reasonably achievable
(ALARA principle) radiation dose. At our institution,
radiation dose for the current volumetric HRCT tech-
nique is approximately 13 versus 9 mSv for an incre-
mental HRCT. For reference, the radiation dose for the
current two view digital chest radiography examina-
tion is 0.05 mSv.
RADIOGRAPHICAL EVALUATION OF
IDIOPATHIC PULMONARY FIBROSIS
The approach to evaluating the HRCT images relies
on evaluation of the predominant findings and their
distribution (Table 2). A level of radiographical con-
fidence in diagnosing UIP can then be applied. The
findings most often associated with UIP include
Table 1 American College of Radiology practice guide-
line for performing a high-resolution computed tomogra-
phy examination8
No i.v. iodinated contrast material
High-spatial-frequency reconstruction algorithm
Slice thickness
2 mm for non-helical CT







Gantry rotation time 1 second
Table 2 Diagnostic categories and high-resolution com-
puted tomography (HRCT) features





No predominant ground glass attenuation
Consistent with usual interstitial pneumonia
Subpleural, basal distribution
Minimal or equivocal honeycomb
Interlobular septal thickening
Traction bronchiectasis
No predominant ground glass attenuation
Suggestive of alternate diagnosis
No honeycomb
With one or more of the following as the predominant
HRCT finding:
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honeycomb, traction bronchiectasis, irregular inter-
lobular septal thickening and GGA. The distribution is
typically basal and peripheral.
In our institution, we interpret HRCT studies of
patients suspected to have IPF as definite UIP, consis-
tent with UIP or suggestive of alternate diagnosis
(Figs. 1–3). Categories listed in Table 2 have been used
in clinical trials for patients with IPF; however, pro-
spective validation of their impact on prognosis or
response to treatment are lacking. A HRCT diagnosis
of definite UIP is defined as a peripheral and basal
distribution of honeycomb with traction bronchiecta-
sis, irregular interlobular septal thickening and
minimal GGA. Honeycomb is a prerequisite for defi-
nite UIP diagnosis. In a study of 54 biopsy-proven UIP
patients, the hazard ratios for basal honeycomb and
upper lobe interlobular septal thickening were 5.4
and 6.3, respectively.11 Honeycomb in at least one lobe
was found to indicate UIP with a 90% sensitivity and
86% specificity in 106 patients with biopsy-proven
UIP.12
To achieve a HRCT diagnosis of consistent with UIP,
there may be questionable, scant or patchy honey-
comb, with traction bronchiectasis and irregular
interlobular septal thickening in a peripheral distri-
bution. Features such as absent honeycomb, promi-
nent GGA, nodules, cysts, mosaicism and/or if the
distribution is uncharacteristic, such as upper lobe
predominance, classify the HRCT as suggestive of
alternate diagnosis.
(a) (b)
Figure 1 Definite usual interstitial
pneumonia. A 92-year-old man with
progressive dyspnea on exertion.
Axial high-resolution computed
tomography image (a) acquired at
the lung base reveals extensive
honeycomb (arrow). Coronal re-
formatted image (b) illustrates
the peripheral subpleural and
lower lung dominant distribution of
honeycomb.
(a) (b)
Figure 2 Consistent with usual
interstitial pneumonia. A 74-year-old
man with dyspnea on exertion and
progressive cough. Axial high-
resolution computed tomography
image (a) acquired at the lung base
reveals patchy, minor, focal honey-
comb (arrow). Coronal reformatted
image (b) illustrates the peripheral
and patch distribution along with
interlobular septal thickening.
(a) (b)
Figure 3 Suggestive of alternate
diagnosis. A 72-year-old woman
with limited exertional capacity due
to worsening breathlessness. Axial
high-resolution computed tomogra-
phy image (a) acquired at the lung
base reveals patch subpleural reticu-
lation (arrow), irregular interlobular
septal thickening (curved arrow) and
areas of lobular sparing (arrow
head). Coronal reformatted image
(b) reveals diffuse and patch distri-
bution. The appearances suggest
possible non-specific interstitial
pneumonitis or chronic hypersensi-
tivity pneumonitis.
SL Schmidt et al.936
© 2009 The Authors
Journal compilation © 2009 Asian Pacific Society of Respirology





Numerous studies have evaluated the agreement
between the clinical/radiographical diagnosis and the
final diagnosis reached after including histopatho-
logical information. The types of patients included in
these studies as well as the clinical settings vary.
Raghu and colleagues prospectively evaluated 59
sequential patients referred to a tertiary care centre
with new onset interstitial lung disease.13 The cases
were reviewed by a single clinician, radiologist and
pathologist independently with the pathological
interpretation used as the gold standard for diagnosis.
The sensitivities for making a correct clinical and
HRCT diagnosis of IPF were 62% and 78.5%, respec-
tively. However, the specificities were respectively
97% and 90%. In a subsequent study, Flaherty et al.
examined 96 patients with either UIP or nonspecific
interstitial pneumonitis (NSIP) based on surgical lung
biopsy results. The HRCT interpretation of definite
UIP had 100% specificity, although the sensitivity was
low at 37%.14 In an even more restrictive study, Sumi-
kawa et al. evaluated the HRCT characteristics of 98
patients with pathologically proven UIP. A HRCT
pattern of definite UIP was seen in only 33 cases
(34%). Twenty-nine cases (30%) had a HRCT sugges-
tive of an alternate diagnosis, namely NSIP.15 These
studies substantiate that HRCT can be used to diag-
nose UIP; however, the sensitivity to detect all cases of
UIP is low.
HRCT studies that are interpreted as UIP with a
high level of confidence are more likely to be concor-
dant with UIP on histopathology. In a blinded pro-
spective evaluation of 91 patients with proven UIP on
surgical lung biopsy, Hunninghake et al. found the
specificity of a confident HRCT diagnosis of UIP was
95% (21/22 cases). A core of experienced pulmonolo-
gists reached a confident UIP/IPF diagnosis with an
87% positive predictive value and a core of radiolo-
gists had a 96% positive predictive value.16 In a subse-
quent study investigators undertook a blinded review
of 176 HRCT studies from patients enrolled in the
Idiopathic Pulmonary Fibrosis International Group
Exploring N-Acetylcysteine I Annual trial17 and ren-
dered three categories of diagnoses (unlikely, prob-
able or very suggestive of UIP). These diagnoses
represented 12.6%, 38.2% and 48.5% of HRCT scans,
respectively.18 The lung biopsy specimens were posi-
tive for UIP in 84.4% of those deemed probable UIP
and 91.7% of those with the diagnosis of very sugges-
tive of UIP. These data corroborate that the level of
confidence in HRCT diagnosis correlates with patho-
logical diagnosis.
HRCT appearance may also aid in determination of
prognosis. In the series by Flaherty et al., HRCT
appearance of definite UIP was associated with a
median survival of 2.08 years. In contrast, UIP
patients where the HRCT was indeterminate or sug-
gestive of an alternate diagnosis, namely NSIP,
median survival increased to 5.76 years.14 These find-
ings are similar to the Sumikawa study where median
survival was worse for patients with HRCT diagnosis
of definite UIP (34.8 months), compared with patients
with HRCT appearance suggestive of alternate diag-
nosis (112 months), although the results were not sta-
tistically significant.15 Quantitative HRCT scoring of
traction bronchiectasis and fibrosis was associated
with mortality.
In aggregate, these studies highlight that HRCT has
a high specificity for diagnosing UIP as verified by
pathology, especially in the setting of a high-
confidence interpretation. However, HRCT cannot
rule out UIP, regardless of the confidence. Therefore, if
the HRCT interpretation is other than definite UIP,
surgical lung biopsy would be warranted to establish




Numerous studies have evaluated the inter-observer
agreement for diagnosing UIP by HRCT. 16,18–20 They
demonstrate moderate levels of kappa (agreement
beyond chance alone) that range from 0.40 to 0.55.
There was less agreement between community-based
versus academic-based radiologists (kappa 0.11–
0.34).20 Community-based physicians were more
likely to assign a diagnosis of UIP/IPF compared with
academic-based physicians.20 The reason for the
differences in interpretation between community-
and academic-based radiologists is unclear. In either
setting, use of a multidisciplinary approach involving




TOMOGRAPHY AS A SURROGATE
While all IPF by definition has UIP as its pathological
correlate, not all UIP is IPF. Several diffuse parenchy-
mal lung diseases can eventually lead to a UIP pattern
on pathology. Clinical studies that evaluate the diag-
nostic process for IPF typically exclude patients
known to have connective tissue disease or an occu-
pational, environmental or medication exposure
known to cause fibrosis. The capability of HRCT to
unravel the original aetiology for the UIP pattern is
unknown. Therefore, a comprehensive evaluation,
including clinical history, physical, laboratory data
and possibly bronchoscopy, is necessary to ensure
that the patient’s disease process is truly idiopathic.
In some cases, the aetiology of a UIP appearance on
HRCT may never be elucidated, such as in chronic
hypersensitivity pneumonitis with an unknown anti-
genic exposure.22 This process may be even more
difficult to achieve with concomitant emphysema,
which has been shown to confound the ability of
thoracic radiologists to make a confident diagnosis
of UIP.23
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Applying the practices used in the aforementioned
clinical trials may be difficult in a community health
practice setting that lacks access to a specialist inter-
pretation of HRCT images. Consistent and expert
HRCT interpretation may be difficult to achieve in
non-specialized centres due to a lower prevalence of
diffuse parenchymal lung disease than in a referral
population. The potential impact of the presence of a
dedicated thoracic radiologist is highlighted by a
recent survey of pulmonologists in the UK.24 When
queried about their management of diffuse parenchy-
mal lung disease, 14% had no access to a thoracic
radiologist. Half as many respondents in specialized
cardiothoracic centres would recommend surgical
lung biopsy in comparison with general hospital pul-
monologists given the same clinical scenario. This
discrepancy was thought to be due to the specialized
imaging and radiologists available at the referral
centres.
A MULTIDISCIPLINARY APPROACH
Given the moderate levels of inter-observer agree-
ment between physicians and the caveats mentioned,
an interactive multidisciplinary approach improves
diagnostic certainty and confidence in regards to the
IIPs and IPF. While HRCT features can accurately
reflect a pathological diagnosis of UIP in some cases,
arriving at a diagnosis of IPF is best supported by a
team approach as outlined by the ATS/ERS consensus
statement on IIP.1
For example, a study was conducted evaluating an
interactive multidisciplinary process encompassing
clinicians, radiologists and pathologists reviewing 58
consecutive cases of IIP.21 The process involved each
physician evaluating the cases alone, and finally in a
process similar to a tumour board where all parties
reviewed the information together. The consensus
diagnosis often differed from the individual clinician,
radiologist or pathologist. Inter-observer agreement
improved from k = 0.39 to k = 0.88 as did diagnostic
confidence. Although histopathological diagnosis
had the greatest impact on final diagnosis, patholo-
gists did consider data such as a history consistent
with hypersensitivity pneumonitis or collagen vas-
cular disease in determining a final diagnosis.20,21
Inter-observer agreement improved among the mul-
tidisciplinary team when the pathologist took the
clinical information into account.
CONCLUSIONS
HRCT can be used as a surrogate to identify the his-
topathological pattern of UIP under the appropriate
conditions. Given the appropriate clinical scenario,
this can yield a confident correct diagnosis of IPF.
A consistent approach should be used to interpret
HRCT for features consistent with UIP and to assign a
level of confidence. A HRCT diagnosis of definite UIP
is sufficient to preclude the need for lung biopsy.
Biopsy would be required in other settings due to the
low sensitivity of HRCT for UIP. A thorough evaluation
and multidisciplinary approach with active discus-
sion between clinicians, radiologists and pathologists
can provide a high level of agreement for a diagnosis
of IPF.
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